Evidence map›Paper›PMID 39456074›Full record

ArticleJournal of cardiothoracic surgery2024

The value of Age-adjusted Charlson and Elixhauser-Van Walraven comorbidity index in predicting prognosis for patients undergoing heart valve surgery.

Xingping Lv, Xiaobin Liu, Chen Li, Wei Zhou, Shuyue Sheng, Yezhou Shen, Tuo Shen, Qimin Ma, Shaolin Ma, Feng Zhu

Abstract read
In one paragraph

Article in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xingping Lv *Department of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Xiaobin Liu *Department of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Chen Li *Department of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Wei ZhouDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Shuyue ShengDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Yezhou ShenDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Tuo ShenDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Qimin MaDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Shaolin MaDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. mslin@sohu.com.
Feng ZhuDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. alexzhujunchi@hotmail.com.

Funding

National Key R&D Program "Stem Cell and Transformation Research" Key Special Project 2019YFA0110601
6 · The paper itself

Abstract

objectiveThis study aims to compare the efficacy of the Age-adjusted Charlson Comorbidity Index (ACCI) and the Elixhauser-Van Walraven Comorbidity Index (ECI-VW) in predicting mortality risk among patients undergoing heart valve surgery.

methodsClinical data were extracted from the INSPIRE Database using R language. The Receiver Operating Characteristic (ROC) Curve was employed to assess the predictive accuracy of ACCI and ECI-VW for in-hospital all-cause mortality and post-surgical all-cause mortality at 7 and 28 days. Subgroup analysis was conducted to validate the application efficacy, and the optimal cutoff value was identified.

resultsThe study included 996 patients, with 931 survivors and 65 cases of in-hospital all-cause mortality. The area under the curve (AUC) for ACCI in predicting in-hospital all-cause mortality was 0.658 (95% CI: 0.584, 0.732), while the AUC for ECI-vw in predicting the same outcome was 0.663 (95% CI: 0.584, 0.741). For predicting all-cause mortality within 7 days post-surgery, the AUC of ACCI was 0.680 (95% CI: 0.04, 0.56), and for ECI-vw, it was 0.532 (95% CI: 0.353, 0.712). Regarding the prediction of all-cause mortality within 28 days after surgery, the AUC for ACCI was 0.724 (95% CI: 0.622, 0.827), and for ECI-vw, it was 0.653 (95% CI: 0.538, 0.69). Patients were categorized into two groups based on the ACCI cutoff value of 3.5, including Group 1 (ACCI < 3.5 points, 823 cases) and Group 2 (ACCI > 3.5 points, 173 cases). The overall survival rate for these two patient groups was calculated using the Kaplan-Meier method, revealing that the 28-day postoperative survival rate for patients in Group 1 was significantly higher than that for patients in Group 2 (P < 0.0001).

conclusionsACCI demonstrates significant predictive value for in-hospital all-cause mortality within 28 days following cardiac valve disease surgery. Patients presenting with an ACCI greater than 3.5 exhibit an increased risk of mortality within 28 days post-surgery compared to those with an ACCI less than 3.5. This finding suggests that the ACCI can serve as a preliminary tool for assessing the prognosis of patients undergoing this type of surgical intervention.

Indexed as

Hospital MortalityAgedAge FactorsCardiac Surgical ProceduresComorbidityFemaleHeart Valve DiseasesHeart Valve Prosthesis ImplantationHeart ValvesHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentROC CurveAge-adjusted Charlson Comorbidity IndexElixhauser-Van Walraven Comorbidity IndexMortalitySurgeryValvular heart disease

Identifiers

PMID39456074
PMCPMC11515313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.